Standout Papers

68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Sc... 2007 2026 2013 2019 720
  1. 68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT (2007)
    Michael Gabriel, Clemens Decristoforo et al. Journal of Nuclear Medicine

Citation Impact

2 by Nobel laureates 4 from Science/Nature 60 standout
Sub-graph 1 of 22

Citing Papers

Glioblastoma Therapy: Past, Present and Future
2024 Standout
[177Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2–3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study
2024 Standout
8 intermediate papers

Works of Dirk Heute being referenced

Response of Recurrent High-Grade Glioma to Treatment with 90Y-DOTATOC
2010
68Ga-DOTA-Tyr3-Octreotide PET in Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT
2007 Standout

Author Peers

Author RNMI Neurology PRM Epidemiology Oncology Last Decade Papers Cites
Dirk Heute 249 555 81 699 550 11 1.1k
Harald Holone 1 3 6 79
Thomas Giel 6 266
Peter Fisk 5 1 4 1 39 1.1k
Marcus Chun‐Wah Yuen 4 1 12 8 45 17 583
Debbie J. Beard 2 2 2 16 270

All Works

Loading papers...

Rankless by CCL
2026